

Table 4 Adverse events of Gemcitabine plus S-1 therapy (n = 39).

Adverse event	Grade				Total n (%)	Grade 3/4, n (%)
	1	2	3	4		
Hematological						
Neutropenia	2	6	13	5	26 (66.7)	18 (46.2)
Thrombocytopenia	10	6	2	3	21 (53.8)	5 (12.8)
Anemia	10	8	3	0	21 (53.8)	3 (7.7)
Febrile neutropenia	0	0	2	2	4 (10.3)	4 (10.3)
Non-hematological						
Rash	5	7	4	0	16 (41)	4 (10.3)
AST increased	10	2	3	0	15 (38.5)	3 (7.7)
ALT increased	11	1	3	0	15 (38.5)	3 (7.7)
Mucositis	4	2	3	0	9 (23.1)	3 (7.7)
Anorexia	3	0	1	0	4 (10.3)	1 (2.6)
Nausea	3	1	0	0	4 (10.3)	0
Cholangitis	0	0	3	0	3 (7.7)	3 (7.7)
Diarrhea	1	0	1	0	2 (5.1)	1 (2.6)
Fever	2	0	0	0	2 (5.1)	0
Creatinine increased	2	0	0	0	2 (5.1)	0
Vomiting	0	0	1	0	1 (2.6)	1 (2.6)
Sepsis	0	0	1	0	1 (2.6)	1 (2.6)

Duodenal ulcer	0	0	1	0	1 (2.6)	1 (2.6)
Constipation	1	0	0	0	1 (2.6)	0
Eye pain	1	0	0	0	1 (2.6)	0
Alopecia	0	1	0	0	1 (2.6)	0
Dyspepsia	0	1	0	0	1 (2.6)	0
Malaise	1	0	0	0	1 (2.6)	0

AST aspartate aminotransferase, *ALT* alanine aminotransferase